					Parent and Trademark Office; U.S DEPARTMENT OF COMMERCE		
Su	Substitute for form 1449A/PTO			COMPLETE IF KNOWN			
I	NFORMATION	DIS	CLOSURE	Application Number	10/554,001		
STATEMENT BY APPLICANT			DITCANE	Filing Date	October 21, 2005		
	STATEMENT BY APPLICANT			First Named Inventor	Mark T. Bilodeau		
				Group Art Unit	To be determined		
(use as many sheets as necessary)				Examiner Name	To be determined		
Sheet	1	of	2	Attorney Docket Number	21299YP		
_							

Examiner	Cite	U.S. Patent Document Kind		Name of Patentee or Applicant	Date of Publication of	
nitials*	No.	Number	Code (if known)	of Cited Document	Cited Document MM-DD-YYYY	
/CC/		5,686,470		Weier, et al.	11/11/1997	
		5,506,219		Robl	04/09/1996	
		5,594,011		McDonald, et al.	01/14/1997	
		5,585,388		Cosford, et al.	12/17/1996	
		2002/0127214		Hemmings	09/12/2002	
		6,060,491		Pruitt, et al.	05/09/2000	
		2004/0106540		Barnett, et al.	06/03/2004	
		2004/0116433		Owens, et al.	06/17/2004	
		2004/0122012		Owens, et al.	06/24/2004	
\top		6,960,584		Carling, et al.	11/01/2005	
		2005/0159422		Lindsley, et al.	07/21/2005	
		2005/0182256		Duggan, et al.	08/18/2005	
		2005/0222155		Bilodeau, et al.	10/06/2005	
		2005/0130977		Lindsley, et al.	06/16/2005	
		2004/0102360		Barnett, et al.	05/27/2004	
		2005/0288294		Duggan, et al.	12/29/2005	
/CC/						

					T DOCUMENTS			
Examiner Cite Initials* No.		Office	Foreign Patent Docume Number	Kind Code (if known)	Name of Patentee or Applican of Cited Document	Cited I	Date of Publication of Cited Document MM-DD-YYYY	
/CC/		EP	0356788		E.R Squibb & Sons, Inc.	03/07/1990		
		PCT	WO 96/15123		The Salk Institute Biotechnolog	y 05/23/1996		
		PCT	WO 96/24584		G.D Searle & Company	08/15/1996		
		PCT	WO 96/31475		Sibia Neurosciences, Inc.	10/10/1996		
		PCT	WO 97/22360		Medical Research Counsil	06/26/1997		
		PCT	WO 01/91754		Peptor Ltd.	12/06/2001		
		PCT	WO 96/23769		Smithkline Beecham PLC.	08/08/1996		
		PCT	WO 02/083138		Merck & Co., Inc.	10/24/2002		
/CC/		PCT	WO 03/084473		Merck & Co., Inc.	10/16/2003		
Examin	er re		/Celia Chang/		Date Considered	07/11/2008		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of bits form with next communication to applicant.

SEND TO: Communication or opticant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form 'IDS Forter' (IDS Folder), Merck & Co., Inc., 7/12/2005 [

Approved for use through 7/51/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05). Information Dischoure Statement by Applicant

					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE		
Su	hstitute for form 1449B/PTO			COMPLETE IF KNOWN			
I	NFORMATION	DIS	CLOSURE	Application Number	10/554,001		
6	TATEMENT BY	AT	DI ICANIT	Filing Date	October 21, 2005		
3	TATEMENT DI	AI	FLICANI	First Named Inventor	Mark T. Bilodeau		
				Group Art Unit	To be determined		
(use as many sheets as necessary)				Examiner Name	To be determined		
Sheet	2	of	2	Attorney Docket Number	21299YP		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
/CC/		Bilodeau, et al. Database on Stn. No. 139:350754, WO 2003/086394				
		Barnett, et al. Database on Stn. No. 139:323527, WO 2003/084473 (203)				
		Zhao, et al. Biorganic & Medicinal Chemistry Letters, Vol. 15 (4), pp. 905-909, Database o Stn. No. 142:211437 (2005)				
		DeFeo-Jones, et al. Molecular Cancer Therapeutics, Vol. 4(2), pg. 271-279 (2005)				
/CC/		Lindsley, et al. Bioorganic & Medicinal Chemistry Letters, Vol. 15(3), pg. 761-764 (2005)				
		3000 30000 3				
	l					

	Date Considered	07/11/2008
--	--------------------	------------